How real-world evidence is impacting regulatory decision-making: 12 recent approvals based on RWE
Volume 2 Offering 12 new use cases of life sciences companies continuing to invest in RWD to advance product approvals before an FDA that is only becoming more accepting of RWE.
How real-world evidence is impacting regulatory decision-making: A collection of 12 recent approvals based on RWE
Volume 1 From the new FDA framework to the urgency of COVID-19, recent events have dramatically accelerated the use of RWE in regulatory decision-making. Now, life sciences organizations are investing heavily in analytics to generate RWE for regulatory submission.
Evaluate pharma world preview 2021: Outlook to 2026
Evaluate’s comprehensive report tracks the expected performance of the biopharma industry between now and 2026, based on Evaluate Pharma’s coverage of the world’s leading pharmaceutical and biotech companies.